Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s
Marie V. Daugan, Margot Revel, Jules Russick, Marie‐Agnès Dragon‐Durey, Christine Gaboriaud, Tania Robe-Rybkine, Victoria Poillerat, Anne Grünenwald, Guillaume Lacroix, Antoine Bougoüin, Maxime Meylan, Virginie Verkarre, Stéphane Oudard, Arnaud Méjean, Yann Vano, Géraldine Perkins, Pierre Validire, Xavier Cathelineau, Rafael Sanchez‐Salas, Diane Damotte, Véronique Frémeaux‐Bacchi, Isabelle Cremer, Catherine Sautès‐Fridman, Wolf H. Fridman, Lubka T. Roumenina
Abstract
Abstract The complement system plays a complex role in cancer. In clear cell renal cell carcinoma (ccRCC), local production of complement proteins drives tumor progression, but the mechanisms by which they do this are poorly understood. We found that complement activation, as reflected by high plasma C4d or as C4d deposits at the tumor site, was associated with poor prognosis in two cohorts of patients with ccRCC. High expression of the C4-activating enzyme C1s by tumor cells was associated with poor prognosis in three cohorts. Multivariate Cox analysis revealed that the prognostic value of C1s was independent from complement deposits, suggesting the possibility of complement cascade–unrelated, protumoral functions for C1s. Silencing of C1s in cancer cell lines resulted in decreased proliferation and viability of the cells and in increased activation of T cells in in vitro cocultures. Tumors expressing high levels of C1s showed high infiltration of macrophages and T cells. Modification of the tumor cell phenotype and T-cell activation were independent of extracellular C1s levels, suggesting that C1s was acting in an intracellular, noncanonical manner. In conclusion, our data point to C1s playing a dual role in promoting ccRCC progression by triggering complement activation and by modulating the tumor cell phenotype and tumor microenvironment in a complement cascade–independent, noncanonical manner. Overexpression of C1s by tumor cells could be a new escape mechanism to promote tumor progression. See related Spotlight by Magrini and Garlanda, p. 855. See article by Daugan et al., p. 909 (40).